BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Nektar Therapeutics, Inc. (“Nektar” or the “Company”) (NASDAQ: NKTR) investors concerning the Company and its officers’ possible violations of federal securities laws.
The investigation concerns whether or not Nektar complied with the federal securities law. On October 1, 2018, a report was published by Plainview LLC alleged that Nektar’s plan to develop NKTR-214 into “a new universal cancer treatment” “has never worked in practice,” and further argued that Nektar’s choice to only disclose certain trial results represented “an unprecedented level of data opacity.” On this news, Nektar’s share price fell, thereby injuring investors.
If you purchased Nektar securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to email@example.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.